[go: up one dir, main page]

PE20070242A1 - Forma cristalina iv de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen - Google Patents

Forma cristalina iv de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen

Info

Publication number
PE20070242A1
PE20070242A1 PE2006000867A PE2006000867A PE20070242A1 PE 20070242 A1 PE20070242 A1 PE 20070242A1 PE 2006000867 A PE2006000867 A PE 2006000867A PE 2006000867 A PE2006000867 A PE 2006000867A PE 20070242 A1 PE20070242 A1 PE 20070242A1
Authority
PE
Peru
Prior art keywords
agomelatin
crystal form
contain
pharmaceutical compositions
preparation procedure
Prior art date
Application number
PE2006000867A
Other languages
English (en)
Inventor
Gerard Coquerel
Julie Linol
Jean-Claude Souvie
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20070242A1 publication Critical patent/PE20070242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UNA FORMA CRISTALINA IV DE AGOMELATINA (N-[2-(7-METOXI-1-NAFTIL)ETIL]ACETAMIDA) DE FORMULA (I), QUE PRESENTA UN DIAGRAMA DE DIFRACCION X SOBRE POLVO CARACTERISTICO. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION DE DICHA FORMA CRISTALINA, EL CUAL CONSISTE EN LLEVAR LA AGOMELATINA A UNA TEMPERATURA DE 110ºC HASTA FUSION COMPLETA DEL PRINCIPIO ACTIVO, LUEGO SE ENFRIA ENTRE 50ºC Y 70ºC Y SE MANTIENE A 70 ºC DURANTE 5 HORAS HASTA RECRISTALIZACION. DICHA FORMA CRISTALINA ES AGONISTA DE LOS RECEPTORES DEL SISTEMA METALONINERGICO Y ANTAGONISTA DEL RECEPTOR 5-HT2C Y ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS DEL SUENO, ESTRES, ANSIEDAD, DEPRESION, PATOLOGIAS CARDIOVASCULARES, INSOMNIO, ENTRE OTRAS
PE2006000867A 2005-08-03 2006-07-19 Forma cristalina iv de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen PE20070242A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508277A FR2889522B1 (fr) 2005-08-03 2005-08-03 Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20070242A1 true PE20070242A1 (es) 2007-05-06

Family

ID=36589248

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000867A PE20070242A1 (es) 2005-08-03 2006-07-19 Forma cristalina iv de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen

Country Status (24)

Country Link
EP (2) EP1752444A1 (es)
JP (1) JP4580371B2 (es)
CN (1) CN100445264C (es)
AR (1) AR057714A1 (es)
AU (1) AU2006203340B2 (es)
BR (1) BRPI0603043A (es)
CA (1) CA2555119A1 (es)
CO (1) CO5780132A1 (es)
EA (1) EA010867B1 (es)
FR (1) FR2889522B1 (es)
GE (1) GEP20094577B (es)
GT (1) GT200600345A (es)
MA (1) MA28450B1 (es)
MX (1) MXPA06008693A (es)
MY (1) MY141306A (es)
NO (1) NO20063518L (es)
NZ (1) NZ548863A (es)
PE (1) PE20070242A1 (es)
SA (1) SA06270254B1 (es)
SG (1) SG130111A1 (es)
TW (1) TWI327564B (es)
UA (1) UA83718C2 (es)
WO (1) WO2007015002A2 (es)
ZA (1) ZA200606455B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101870662B (zh) * 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
CL2011001405A1 (es) 2010-06-10 2012-03-30 Gador S A Conicet Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN102690210A (zh) 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN102503886B (zh) * 2011-10-11 2013-09-11 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
ES2634243T3 (es) 2011-11-30 2017-09-27 Ratiopharm Gmbh Complejo de agomelatina-urea y formas cristalinas del mismo
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
CN102643208B (zh) * 2012-04-14 2013-11-06 中山大学 一种阿戈美拉汀ⅰ晶型的制备方法
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
PL3075724T3 (pl) 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Stała postać agomelatyny
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
GEP20094577B (en) 2009-01-12
JP2007051141A (ja) 2007-03-01
EP2008994A1 (fr) 2008-12-31
CN100445264C (zh) 2008-12-24
EA010867B1 (ru) 2008-12-30
AU2006203340A1 (en) 2007-02-22
BRPI0603043A (pt) 2007-03-20
SA06270254B1 (ar) 2010-08-02
EP1752444A1 (fr) 2007-02-14
TW200736198A (en) 2007-10-01
SG130111A1 (en) 2007-03-20
EA200601271A1 (ru) 2007-02-27
FR2889522A1 (fr) 2007-02-09
CN1907957A (zh) 2007-02-07
FR2889522B1 (fr) 2007-12-28
AU2006203340B2 (en) 2012-07-19
MXPA06008693A (es) 2007-02-02
WO2007015002A3 (fr) 2007-04-12
WO2007015002A2 (fr) 2007-02-08
CO5780132A1 (es) 2007-07-31
AR057714A1 (es) 2007-12-12
JP4580371B2 (ja) 2010-11-10
MA28450B1 (fr) 2007-03-01
CA2555119A1 (fr) 2007-02-03
ZA200606455B (en) 2007-12-27
NZ548863A (en) 2008-03-28
MY141306A (en) 2010-04-16
UA83718C2 (ru) 2008-08-11
NO20063518L (no) 2007-02-05
HK1098129A1 (zh) 2007-07-13
TWI327564B (en) 2010-07-21
GT200600345A (es) 2007-03-28

Similar Documents

Publication Publication Date Title
PE20070242A1 (es) Forma cristalina iv de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
PE20070213A1 (es) Nueva forma cristalina iii de la agometalina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
PE20070365A1 (es) Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
PE20040974A1 (es) Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que los contienen y procedimientos para su preparacion
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
PE20071325A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica
CO5640073A2 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
EP2194066A4 (en) MODIFIED CONSTANT ANTIBODY REGION
PE20080174A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de la ansiedad generalizada
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
PE20091557A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
EP2197438A4 (en) HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
GT200600158A (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
EP2437732A4 (en) COMBINATION OF DOPAMINAGONISTS AND FIRST-PHASE INSULIN SECRETAGOGEN FOR THE TREATMENT OF METABOLISM DISEASES
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
AR062114A1 (es) Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos.
ECSP066529A (es) Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
NO20084677L (no) Anvendelse av kombinasjonspreparater som inneholder trombinreseptorantagonister for behandling av hjerte-karforstyrrelser

Legal Events

Date Code Title Description
FC Refusal